Advertisement

Hepatic disorders associated with exogenous sex steroids: MR imaging findings

  • Cathryn L. HuiEmail author
  • Zhen Jiang Lee
Review
Part of the following topical collections:
  1. CME articles

Abstract

Objective

To describe the MRI findings of the effects of exogenous sex steroids on the liver.

Findings

Estrogens, progesterone and synthetic testosterone are exogenous sex steroids that may result in a variety of liver diseases, including tumour formation and vascular disorders. These hormones are mainly administered in the form of the oral contraceptive pill (OCP) and anabolic steroids. Both are implicated in hepatic adenoma formation. The HNF-1α-mutated and inflammatory adenoma subgroups are more commonly seen in association with the OCP whereas there is an increased incidence of the β-catenin positive subtype with anabolic steroid use. Furthermore, anabolic steroids are associated with hepatocellular carcinoma resulting from malignant transformation of β-catenin positive adenomas. The oral contraceptive pill may also induce vascular disorders within the liver, some of which are related to the prothrombotic effect of the hormones, such as hepatic and portal vein thrombosis. Other hepatic vascular abnormalities resulting from exogenous sex steroids include veno-occlusive disease and peliosis hepatis.

Keywords

MRI Liver Hepatic adenoma Oral contraceptive pill Anabolic steroids Exogenous sex steroids Hepatic vascular disorders 

Notes

Acknowledgements

We thank Hock Kua, pathologist, for reviewing the pathological findings in our cases.

Compliance with ethical standards

Conflicts of interest

The authors have no conflicts of interest.

References

  1. 1.
    Katabathina VS, Menias CO, Shanbhogue AK, Jagirdar J, Paspulati RM, Prasad SR. Genetics and imaging of hepatocellular adenomas: 2011 update. Radiographics. 2011;31(6):1529–43.Google Scholar
  2. 2.
    Dhingra S, Fiel MI. Update on the new classification of hepatic adenomas: clinical, molecular, and pathologic characteristics. Arch Pathol Lab Med. 2014;138(8):1090–7.Google Scholar
  3. 3.
    McInnes MD, Hibbert RM, Inacio JR, Schieda N. Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging: A Systematic Review. Radiology. 2015;277(2):413–23.Google Scholar
  4. 4.
    Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50(2):481–9.Google Scholar
  5. 5.
    Yoneda N, Matsui O, Kitao A, Kozaka K, Kobayashi S, Sasaki M, et al. Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background. Radiographics. 2016;36(7):2010–27.Google Scholar
  6. 6.
    Rebouissou S, Imbeaud S, Balabaud C, Boulanger V, Bertrand-Michel J, Terce F, et al. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem. 2007;282(19):14437–46.Google Scholar
  7. 7.
    van Aalten SM, Thomeer MG, Terkivatan T, Dwarkasing RS, Verheij J, de Man RA, et al. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology. 2011;261(1):172–81.Google Scholar
  8. 8.
    Grazioli L, Bondioni MP, Haradome H, Motosugi U, Tinti R, Frittoli B, et al. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology. 2012;262(2):520–9.Google Scholar
  9. 9.
    Ronot M, Bahrami S, Calderaro J, Valla DC, Bedossa P, Belghiti J, et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology. 2011;53(4):1182–91.Google Scholar
  10. 10.
    Bieze M, van den Esschert JW, Nio CY, Verheij J, Reitsma JB, Terpstra V, et al. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol. 2012;199(1):26–34.Google Scholar
  11. 11.
    Socas L, Zumbado M, Perez-Luzardo O, Ramos A, Perez C, Hernandez JR, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med. 2005;39(5):e27.Google Scholar
  12. 12.
    Hardt A, Stippel D, Odenthal M, Holscher AH, Dienes HP, Drebber U. Development of hepatocellular carcinoma associated with anabolic androgenic steroid abuse in a young bodybuilder: a case report. Case Rep Pathol. 2012;2012:195607.Google Scholar
  13. 13.
    Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Sanada J, et al. Hepatocellular Carcinoma with beta-Catenin Mutation: Imaging and Pathologic Characteristics. Radiology. 2015;275(3):708–17.Google Scholar
  14. 14.
    Solbach P, Potthoff A, Raatschen HJ, Soudah B, Lehmann U, Schneider A, et al. Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report. BMC Gastroenterol. 2015;15:60.Google Scholar
  15. 15.
    Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Koda W, et al. Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology. 2012;265(3):780–9.Google Scholar
  16. 16.
    Sutherland T, Seale M, Yap K. Part 1: MRI features of focal nodular hyperplasia with an emphasis on hepatobiliary contrast agents. Journal of medical imaging and radiation oncology. 2014;58(1):50–5.Google Scholar
  17. 17.
    Mohajer K, Frydrychowicz A, Robbins JB, Loeffler AG, Reed TD, Reeder SB. Characterization of hepatic adenoma and focal nodular hyperplasia with gadoxetic acid. J Magn Reson Imaging. 2012;36(3):686–96.Google Scholar
  18. 18.
    Sarma A, Shaaban AM, Heilbrun ME, Rezvani M. Two cases of near-complete regression of focal nodular hyperplasia of the liver: case reports and review of the literature. Radiology case reports. 2012;7(3).Google Scholar
  19. 19.
    Mathieu D, Kobeiter H, Cherqui D, Rahmouni A, Dhumeaux D. Oral contraceptive intake in women with focal nodular hyperplasia of the liver. The Lancet. 1998;352(9141):1679–80.Google Scholar
  20. 20.
    Colli A, Fraquelli M, Massironi S, Colucci A, Paggi S, Conte D. Elective surgery for benign liver tumours. The Cochrane Library. 2007.Google Scholar
  21. 21.
    Mathieu D, Kobeiter H, Maison P, Rahmouni A, Cherqui D, Zafrani ES, et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology. 2000;118(3):560–4.Google Scholar
  22. 22.
    Anderson SW, Kruskal JB, Kane RA. Benign hepatic tumors and iatrogenic pseudotumors. Radiographics. 2009;29(1):211–29.Google Scholar
  23. 23.
    Savastano S, San Bortolo O, Velo E, Rettore C, Altavilla G. Pseudotumoral appearance of peliosis hepatis. AJR Am J Roentgenol. 2005;185(2):558–9.Google Scholar
  24. 24.
    Torabi M, Hosseinzadeh K, Federle MP. CT of nonneoplastic hepatic vascular and perfusion disorders. Radiographics. 2008;28(7):1967–82.Google Scholar
  25. 25.
    Iannaccone R, Federle MP, Brancatelli G, Matsui O, Fishman EK, Narra VR, et al. Peliosis hepatis: spectrum of imaging findings. AJR Am J Roentgenol. 2006;187(1):W43–52.Google Scholar
  26. 26.
    Verswijvel G, Janssens F, Colla P, Mampaey S, Verhelst H, Van Eycken P, et al. Peliosis hepatis presenting as a multifocal hepatic pseudotumor: MR findings in two cases. Eur Radiol. 2003;13 Suppl 4:L40–4.Google Scholar
  27. 27.
    Hong GS, Kim KW, An J, Shim JH, Kim J, Yu ES. Focal type of peliosis hepatis. Clin Mol Hepatol. 2015;21(4):398–401.Google Scholar
  28. 28.
    Kim SH, Lee JM, Kim WH, Han JK, Lee JY, Choi BI. Focal peliosis hepatis as a mimicker of hepatic tumors: radiological-pathological correlation. J Comput Assist Tomogr. 2007;31(1):79–85.Google Scholar
  29. 29.
    Ferrozzi F, Tognini G, Zuccoli G, Cademartiri F, Pavone P. Peliosis hepatis with pseudotumoral and hemorrhagic evolution: CT and MR findings. Abdom Imaging. 2001;26(2):197–9.Google Scholar
  30. 30.
    Ferral H, Behrens G, Lopera J. Budd-Chiari syndrome. AJR Am J Roentgenol. 2012;199(4):737–45.Google Scholar
  31. 31.
    Cura M, Haskal Z, Lopera J. Diagnostic and interventional radiology for Budd-Chiari syndrome. Radiographics. 2009;29(3):669–81.Google Scholar
  32. 32.
    Brancatelli G, Vilgrain V, Federle MP, Hakime A, Lagalla R, Iannaccone R, et al. Budd-Chiari syndrome: spectrum of imaging findings. AJR Am J Roentgenol. 2007;188(2):W168–76.Google Scholar
  33. 33.
    Aronson JK. Meyler's side effects of drugs: the international encyclopedia of adverse drug reactions and interactions: Elsevier; 2015.Google Scholar
  34. 34.
    Erden A. Budd-Chiari syndrome: a review of imaging findings. Eur J Radiol. 2007;61(1):44–56.Google Scholar
  35. 35.
    Lee HK, Park SJ, Yi BH, Yeon EK, Kim JH, Hong HS. Portal vein thrombosis: CT features. Abdom Imaging. 2008;33(1):72–9.Google Scholar
  36. 36.
    Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol. 2018;31(3):315–29.Google Scholar
  37. 37.
    Margini C, Berzigotti A. Portal vein thrombosis: The role of imaging in the clinical setting. Dig Liver Dis. 2017;49(2):113–20.Google Scholar
  38. 38.
    Jha RC, Khera SS, Kalaria AD. Portal Vein Thrombosis: Imaging the Spectrum of Disease With an Emphasis on MRI Features. AJR Am J Roentgenol. 2018;211(1):14–24.Google Scholar
  39. 39.
    Zhou H, Wang YX, Lou HY, Xu XJ, Zhang MM. Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features. Korean J Radiol. 2014;15(2):218–25.Google Scholar
  40. 40.
    Erturk SM, Mortele KJ, Binkert CA, Glickman JN, Oliva MR, Ros PR, et al. CT features of hepatic venoocclusive disease and hepatic graft-versus-host disease in patients after hematopoietic stem cell transplantation. AJR Am J Roentgenol. 2006;186(6):1497–501.Google Scholar
  41. 41.
    Mortele KJ, Van Vlierberghe H, Wiesner W, Ros PR. Hepatic veno-occlusive disease: MRI findings. Abdom Imaging. 2002;27(5):523–6.Google Scholar
  42. 42.
    Yang S, Wu J, Lei S. CT Features of Hepatic Veno-occlusive Disease: A Meta-analysis. Acad Radiol. 2018;25(3):328–37.Google Scholar
  43. 43.
    Dumont C, Lambert M, Van Beers BE. MR imaging findings in a patient with hepatic veno-occlusive disease. Acta Gastroenterol Belg. 2004;67(2):236–8.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Monash ImagingMonash HealthMelbourneAustralia

Personalised recommendations